Printer Friendly

Drug patent is lost.

Drugs giant GlaxoSmithKline has lost a UK patent case on its top-selling asthma drug.

The High Court ruling yesterday opens the way for cheaper copycat versions of Seretide - also known as Advair - to go on sale in Britain, potentially taking a sizeable chunk out of GSK's profits.

India's Cipla Ltd, US-based Ivax Corp and two other companies manufacturing generic versions of GSK's asthma treatment had challenged a key patent on the drug which expires in 2013.

A spokesman for GSK, which employs 2,200 people in Barnard Castle, County Durham and Ulverston in Cumbria, said the company would be appealing against the ruling.

Seretide/Advair was Glaxo's top-selling product in 2003.

It built global sales of pounds 2.2bn, with 6pc of the total being generated in Britain.

While analysts say the ruling will only affect a small part of Glaxo's market, they fear it could pave the way for further challenges which may affect other countries.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Features
Publication:The Journal (Newcastle, England)
Date:Mar 20, 2004
Previous Article:Amec's second contract in days.
Next Article:Profits leap at Nike.

Related Articles
SIBIA Neurosciences announces issuance of United States patents.
Sandoz to buy Sabex.
Is there a biomedical anticommons? Patent holders have a strong interest in profiting from their patents.
Quo vadis, Novartis? It's kind of ironic that Novartis, a company known for its ethical stance and for helping the poor in developing countries...

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters